Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
78 hedge funds and large institutions have $546M invested in Revance Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 9 closing their positions.
97% more call options, than puts
Call options by funds: $687K | Put options by funds: $349K
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
1% more capital invested
Capital invested by funds: $540M → $546M (+$6.08M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 81 → 78 (-3)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$42M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.46M |
| 3 |
Goldman Sachs
New York
|
+$2.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.56M |
| 5 |
PC
PointState Capital
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$6.1M |
| 2 |
Bank of New York Mellon
New York
|
-$2.55M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.89M |
| 4 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
-$1.51M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.19M |
RVNC Hedge Fund Activity: Q1 2017 in Review
78 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2017, worth a combined $546M — up 1.1% from $540M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RVNC positions and 9 closed out — a net gain of 2 holders — while 23 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $42M. The largest seller was Franklin Resources, cutting an estimated $6.1M.
- 78 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2017, down from 81 in Q4 2016.
- Funds reported $546M of Revance Therapeutics, Inc. stock for Q1 2017, up 1.1% quarter-over-quarter.
- 11 funds opened new Revance Therapeutics, Inc. positions in Q1 2017 and 9 closed out, a net change of +2 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $42M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2017 was Franklin Resources, an estimated $6.1M sold.
Based on aggregated 13F filings for Q1 2017.